JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

SOCS1 Inhibits IL-6-Induced CD155 Overexpression in Lung Adenocarcinoma

  • 0Laboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosio Villegas", Mexico City 14080, Mexico.
International Journal of Molecular Sciences +

|

November 27, 2024

|

November 27, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Interleukin-6 (IL-6) upregulates CD155 (poliovirus receptor) in lung adenocarcinoma, promoting immune evasion. Suppressor of cytokine signaling 1 (SOCS1) inhibits this IL-6-induced CD155 overexpression, offering potential therapeutic targets.

Area Of Science

  • Immunology
  • Oncology
  • Molecular Biology

Background

  • CD155 (poliovirus receptor) overexpression is linked to cancer immune evasion and immunotherapy resistance.
  • Mechanisms regulating CD155 overexpression, particularly in the tumor microenvironment, are not fully understood.
  • Proinflammatory factors are implicated in CD155 expression.

Purpose Of The Study

  • To investigate the effect of interleukin-6 (IL-6) on CD155 expression in lung adenocarcinoma.
  • To elucidate the role of suppressor of cytokine signaling 1 (SOCS1) in regulating IL-6-mediated CD155 expression.

Main Methods

  • Analysis of mRNA and protein levels of CD155 in lung adenocarcinoma cell lines.
  • Bioinformatics analysis using patient data and serum samples.
  • Investigation of SOCS1 expression and silencing effects on CD155 levels following IL-6 stimulation.

Main Results

  • A positive correlation was observed between IL-6, CD155 mRNA, and protein levels in lung adenocarcinoma.
  • This correlation was validated through bioinformatics analysis and patient biopsies/serum.
  • Lung adenocarcinoma cells expressing SOCS1 resisted IL-6-induced CD155 upregulation; SOCS1 silencing reversed this resistance.

Conclusions

  • IL-6 and SOCS1 are critical regulators of CD155 expression in lung adenocarcinoma.
  • Understanding these regulatory mechanisms can improve biomarker development for immunotherapy efficacy.
  • This research provides insights for novel combination therapies targeting immune checkpoints.

Keywords: